Issue Stories

Cystic fibrosis ASR

For the detection of 29 mutations

The Elucigene CF29 ASR reagents are for the detection of 29 cystic fibrosis mutations using ARMS technology. The Elucigene reagents have been developed specifically to meet the requirements of the “Laboratory Standards and Guidelines for Population-based Cystic Fibrosis Carrier Screening” published by the American College of Medical Genetics.
     CF 29 consists of four primer mixes, dilution buffer and a gel loading dye. It is capable of detecting the core panel of 25 mutations selected by the ACMG in addition to four others. El;ucigene’s use of ARMS allele specific amplification is able to discriminate between the benign 506, 507 and 508 polymorphisms directly, eliminating the need for reflex testing. ARMS is a simple yet accurate technique that only requires a thermal cycler and gel electrophoresis equipment. Poly-T ASR reagents are available separately for determination of intron 8 Poly-T status when appropriate (i.e. R117H carriers).
Orchid Diagnostics
www.orchid.com
Keywords: ASR, molecular diagnostics

|
|

MEDIA CENTER

Interactive Media
Resources
Classifieds
Calendar
Consumer Resources
Media Kit
Advertiser Index
EAB
Reprints

ADDITIONAL ONLINE RESOURCES

Allied Healthcare
Medical Education
24X7mag
Chiropractic Products Magazine
Clinical Lab Products (CLP)
Orthodontic Products
The Hearing Industry Resource
HME Today
Rehab Management
Physical Therapy Products
Plastic Surgery Products
Imaging Economics
Medical Imaging
RT Magazine
Sleep Review
SynerMed Communications
IMED Communications
Practice Growth
Practice Builders
powered by:
Copyright © 2009 Ascend Media LLC | Clinical Lab Products | All Rights Reserved.
Privacy Policy | Terms of Service